Login / Signup

Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine.

Ling QianKun ChenChang-Hong WangZhen ChenZhiqiang Meng
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Chelidonine suppresses NRAS-mutant cancer cell growth and could have utility as a new treatment for such malignancies.
Keyphrases
  • wild type
  • papillary thyroid
  • signaling pathway
  • squamous cell
  • cancer therapy
  • squamous cell carcinoma
  • combination therapy
  • drug delivery
  • young adults
  • lymph node metastasis